详细介绍
粘蛋白(MUC2)重组蛋白
广州健仑生物科技有限公司
粘蛋白2是一种消化道肿瘤相关的分泌型粘蛋白,属粘蛋白家族成员。该抗体主要表达于小肠和结肠的杯状细胞、大部分的结肠癌和胃癌。
我司还提供其它进口或国产试剂盒:登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。
欢迎咨询
欢迎咨询
粘蛋白(MUC2)重组蛋白
【产品介绍】
细胞定位:细胞浆
克隆号:MRQ-18
同型:IgG
适用组织:石蜡/冰冻
阳性对照:直肠/直肠癌
抗原修复:热修复(EDTA)
抗体孵育时间:30-60min
产品编号 | 抗体名称 | 克隆型别 |
OB160 | Melanoma Associated Antigen(黑色素瘤相关抗原) | KBA.62 |
OB161 | Melanoma(黑色素瘤) | HMB-45 |
OB162 | Mesothelial Cell 间皮细胞 | HBME-1 |
OB163 | MGMT(甲基鸟嘌呤甲基转移酶) | UMAB56 |
OB164 | MHA (髓样/组织细胞抗原) | MAC387 |
OB165 | MLH1(错配修复蛋白1) | ES05 |
OB166 | MPO(髓过氧化物酶) | polyclonal |
OB167 | MSH2(错配修复蛋白2) | G219-1129 |
OB168 | MSH6(错配修复蛋白6) | SP93 |
OB169 | MUC1(粘蛋白1) | MRQ-17 |
OB170 | MUC2(粘蛋白2) | MRQ-18 |
OB171 | MUC5AC(粘蛋白5AC) | MRQ-19 |
OB172 | MUM1(多发性骨髓瘤致癌蛋白) | MRQ-8 |
OB173 | MyoD1(横纹肌肉瘤标志) | EP212 |
OB174 | Myogenin(肌浆蛋白) | F5D |
OB175 | Myoglobin(肌红蛋白) | polyclonal |
OB176 | Myoglobin(肌红蛋白) | MGN01 |
OB177 | Myosin Heavy Chain (Smooth Muscle)肌球蛋白重链(平滑?。?SMMHC | SMMS-1 |
OB178 | Napsin A(天冬氨酸蛋白酶4) | MRQ-60 |
OB179 | N-Cadherin (钙粘附蛋白-N) | 6G11 |
OB180 | Nestin (巢蛋白) | 10C2 |
想了解更多的产品及服务请扫描下方二维码:
【公司名称】 广州健仑生物科技有限公司
【市场部】 欧
【】
【腾讯 】
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室
主要作者Richard P. Phipps博士表示:事实上,一些减肥药包括抗抑郁药或抗成瘾药物,并没有在分子水平上解决脂肪细胞的堆积。尽管40年前就已经发现Thy1,在其他情况下其已被研究,但它的真实分子功能却是未知的。Phipps实验室*报道在脂肪细胞发育过程中Thy1表达缺失,这表明肥胖可以通过恢复Thy1来治疗。
他们也正在努力开发一种抗肥胖药物,Thy1肽,其发明已申请了保护。自1989年以来,Phipps一直在调查Thy1。研究的目标是防止或减少肥胖,我们已经展示了如何做到这一点的基本原则。我们相信,体重增加不一定只是吃的越来越少或锻炼的一个结果。我们的重点是参与脂肪细胞发育的复杂网络。
研究人员研究了小鼠和人来源的细胞系,确认Thy1功能的缺失会促进更多的脂肪细胞。缺乏Thy1蛋白质小鼠、喂食高脂肪饮食后,相比于也吃相同高脂肪饮食的正常对照组小鼠,获得了更多的重量。
Phipps和他的同事正在继续调查为什么细胞有潜力能转化脂肪细胞以及为什么当Thy1关闭脂肪会积累更快。目前尚不清楚是否Thy1的水平在不同人出生时就不同,或者Thy1的水平是否由于时间发展和暴露于各种环境因素而改变。
为了解决后一个问题,Phipps实验室分别研究化学品即被称为肥胖基因如双酚A(BPA),阻燃剂和邻苯二甲酸盐是否能减少人体细胞Thy1的表达,促进肥胖。
Lead author Richard P. Phipps, PhD, said: In fact, some diet pills, including anti-depression drugs or anti-addictive drugs, did not address the accumulation of fat cells at the molecular level. Although Thy1 was discovered 40 years ago and has been studied in other contexts, its true molecular function is unknown. Phipps Laboratories first reported a loss of Thy1 expression during adipocyte development, suggesting that obesity can be treated by restoring Thy1.
They are also working to develop an anti-obesity drug, the Thy1 peptide, whose invention has been claimed for international patent protection. Phipps has been investigating Thy1 since 1989. The goal of the study is to prevent or reduce obesity, and we have demonstrated the basic principles of how to do this. We believe that weight gain is not necessarily just a consequence of eating less or exercising. Our focus is on the complex networks involved in fat cell development.
Researchers studied mouse and human-derived cell lines, confirming that loss of Thy1 function promotes more fat cells. Lack of Thy1 protein mice, after feeding a high-fat diet, gained more weight than normal control mice that also eaten the same high-fat diet.
Phipps and his colleagues are continuing to investigate why cells have the potential to transform fat cells and why fat accumulates faster when Thy1 is turned off. It is unclear whether Thy1 levels differ at birth or whether Thy1 levels change due to time development and exposure to various environmental factors.
To solve the latter problem, Phipps Laboratories separay studied whether chemicals called obesity genes such as bisphenol A (BPA), flame retardants and phthalates reduce Thy1 expression in human cells and promote obesity.